help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wøjdemann, M.
Right arrow Articles by Holst, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wøjdemann, M.
Right arrow Articles by Holst, J. J.
The Journal of Clinical Endocrinology & Metabolism Vol. 84, No. 7 2513-2517
Copyright © 1999 by The Endocrine Society

Original Studies

Inhibition of Sham Feeding-Stimulated Human Gastric Acid Secretion by Glucagon-Like Peptide-2

Morten Wøjdemann, Andre Wettergren, Bolette Hartmann, Linda Hilsted and Jens J. Holst

Departments of Surgery (M.W., A.W.) and Clinical Biochemistry (L.H.), Rigshospitalet, DK-2100; Medical Physiology (B.H., J.J.H.), The Panum Institute DK-2200, University of Copenhagen, Copenhagen, Denmark

Address all correspondence and requests for reprints to: Jens J. Holst, Department of Medical Physiology, The Panum Institute, Blegdamsvej 3C, DK-2200 Copenhagen, Denmark. E-mail: holst{at}mfi.ku.dk

Glucagon-like peptide (GLP)-2 is formed from proglucagon in the intestinal L cells and is secreted postprandially in parallel with the insulinotropic hormone GLP-1, the latter of which, in addition, acts to inhibit gastric secretion and motility by inhibiting central parasympathetic outflow. We now studied the effect of GLP-2 on gastric secretion stimulated by sham feeding to test the hypothesis that also GLP-2 acts as an enterogastrone. Eight healthy volunteers were studied twice on separate days. They were sham fed with and without GLP-2 infused iv at a rate of 0.8 pmol/kg·min. Gastric contents were aspirated continuously by a nasogastric tube for determination of acid secretion, volume, and osmolarity. Sham feeding increased gastric acid secretion nearly 5-fold. Infusion of GLP-2 reduced incremental acid secretion by 65 ± 6%, compared with saline infusion ({Delta}8.75 ± 0.37 vs. {Delta}3.04 ± 0.47 mmol x 60 min; P < 0.01). Plasma concentrations of GLP-2 rose from a basal mean of 3.3 ± 0.9 to a mean of 115 ± 8 pmol/L (range, 57–149 pmol/L) during infusion of GLP-2 and remained at basal level during saline infusion. Plasma concentrations of GLP-1, gastrin, cholecystokinin, and secretin remained low and unchanged on both study days. We conclude that GLP-2 is a powerful inhibitor of gastric acid secretion in man. Further investigations will show to what extent GLP-2 contributes to the inhibitory effects on gastric secretion exerted by hormones from the distal small intestine, under physiological circumstances.




This article has been cited by other articles:


Home page
 Nutr Clin PractHome page
Y. A. Ching, K. Gura, B. Modi, and T. Jaksic
Pediatric Intestinal Failure: Nutrition, Pharmacologic, and Surgical Approaches
Nutr Clin Pract, December 1, 2007; 22(6): 653 - 663.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. J. Hare, B. Hartmann, H. Kissow, J. J. Holst, and S. S. Poulsen
The Intestinotrophic Peptide, GLP-2, Counteracts Intestinal Atrophy in Mice Induced by the Epidermal Growth Factor Receptor Inhibitor, Gefitinib
Clin. Cancer Res., September 1, 2007; 13(17): 5170 - 5175.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. Ferrone and J. S Scolapio
Teduglutide for the Treatment of Short Bowel Syndrome
Ann. Pharmacother., June 1, 2006; 40(6): 1105 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. Stephens, B. Stoll, J. Cottrell, X. Chang, M. Helmrath, and D. G. Burrin
Glucagon-like peptide-2 acutely increases proximal small intestinal blood flow in TPN-fed neonatal piglets
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2006; 290(2): R283 - R289.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
D. B. Henriksen
The Gut Feeling of Bone Remodeling
IBMS BoneKEy, November 1, 2005; 2(11): 16 - 23.
[Full Text] [PDF]

Home page
 GutHome page
P B Jeppesen, E L Sanguinetti, A Buchman, L Howard, J S Scolapio, T R Ziegler, J Gregory, K A Tappenden, J Holst, and P B Mortensen
Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients
Gut, September 1, 2005; 54(9): 1224 - 1231.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. A. Koehler, B. Yusta, and D. J. Drucker
The HeLa Cell Glucagon-Like Peptide-2 Receptor Is Coupled to Regulation of Apoptosis and ERK1/2 Activation through Divergent Signaling Pathways
Mol. Endocrinol., February 1, 2005; 19(2): 459 - 473.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. G. Burrin, B. Stoll, X. Guan, L. Cui, X. Chang, and J. J. Holst
Glucagon-Like Peptide 2 Dose-Dependently Activates Intestinal Cell Survival and Proliferation in Neonatal Piglets
Endocrinology, January 1, 2005; 146(1): 22 - 32.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J Thulesen, B Hartmann, K J Hare, H Kissow, C Orskov, J J Holst, and S S Poulsen
Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice
Gut, August 1, 2004; 53(8): 1145 - 1150.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
J. L. Estall and D. J. Drucker
Dual Regulation of Cell Proliferation and Survival via Activation of Glucagon-Like Peptide-2 Receptor Signaling
J. Nutr., November 1, 2003; 133(11): 3708 - 3711.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
P. B. Jeppesen
Clinical Significance of GLP-2 in Short-Bowel Syndrome
J. Nutr., November 1, 2003; 133(11): 3721 - 3724.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
D J Drucker
Gut adaptation and the glucagon-like peptides
Gut, March 1, 2002; 50(3): 428 - 435.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. J. Drucker
Glucagon-Like Peptide 2
J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1759 - 1764.
[Abstract] [Full Text]

Home page
 J. Nutr.Home page
J. B. van Goudoever, B. Stoll, B. Hartmann, J. J. Holst, P. J. Reeds, and D. G. Burrin
Secretion of Trophic Gut Peptides Is Not Different in Bolus- and Continuously Fed Piglets
J. Nutr., March 1, 2001; 131(3): 729 - 732.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
D. J. Drucker
Minireview: The Glucagon-Like Peptides
Endocrinology, February 1, 2001; 142(2): 521 - 527.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
P B Jeppesen, B Hartmann, J Thulesen, B S Hansen, J J Holst, S S Poulsen, and P B Mortensen
Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon
Gut, September 1, 2000; 47(3): 370 - 376.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Lovshin, J. Estall, B. Yusta, T. J. Brown, and D. J. Drucker
Glucagon-like Peptide (GLP)-2 Action in the Murine Central Nervous System Is Enhanced by Elimination of GLP-1 Receptor Signaling
J. Biol. Chem., June 8, 2001; 276(24): 21489 - 21499.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1999 by The Endocrine Society